Table 1.
Patient Demographics, Tumor Characteristics, Comorbid Conditions, and Concomitant Medications
| Characteristic | All Patients | Patients With Abnormal Decline of LVEF |
|---|---|---|
| Patients analyzed | 30 | 10 |
| Race | ||
| European American | 21 | 9 |
| African American | 9 | 1 |
| Age (years) | ||
| Median | 53.1 | 57.6 |
| Range | 35–76 | 47–66 |
| Tumor type: ductal | 30 | 10 |
| Tumor grade | ||
| I | 6 | 2 |
| II | 13 | 6 |
| III | 11 | 2 |
| TNM stage | ||
| IIA | 16 | 6 |
| IIB | 8 | 2 |
| IIIA | 5 | 1 |
| IIIC | 1 | 1 |
| Hormone receptor status | ||
| ER+, PR+/Her2-neu | 20 | 6 |
| ER−, PR− | 9 | |
| ER−/PR+ | 1 | 1 |
| HER2+ | 1 | 1 |
| Triple negative | 9 | 2 |
| Lymph node positive | 20 | 6 |
| Comorbidity and medications | ||
| Hypertension | 9 | 4 |
| Hydrochlorothiazide, 12.5 mg; metoprolol, 25 mg; candesartan, 16 mg; nebivolol, 10 mg; amlodipine, 10 mg; valsartan, 12.5 mg; lisinopril, 10 mg | ||
| Diabetes mellitus | 6 | 3 |
| Metformin, 1,000 mg; insulin glargine, 100 U/ml | ||
| Coronary artery disease | 1 | 1 |
| Atenolol, 25 mg | ||
| Autoimmune diseases | ||
| Asthma | 1 | |
| Albuterol; mometasone |